Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lefkowitz

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Cancer Discovery|June 23, 2019
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon CancerYijun Gao, Ann Maria, Na Na, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Melanoma Research|October 30, 2016
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanomaAlexander N Shoushtari, Mark J Bluth, Debra A Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesChung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Cancer Immunology Research|January 18, 2018
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 BlockadeCharlotte E Ariyan, Mary Sue Brady, Robert H Siegelbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Cancer Discovery|June 23, 2019
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon CancerYijun Gao, Ann Maria, Na Na, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Melanoma Research|October 30, 2016
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanomaAlexander N Shoushtari, Mark J Bluth, Debra A Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesChung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Cancer Immunology Research|January 18, 2018
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 BlockadeCharlotte E Ariyan, Mary Sue Brady, Robert H Siegelbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Pageof 9